Ome Bei Sodbrennen Tad (Omeprazole)

Omeprazole, the active ingredient in Ome Bei Sodbrennen Tad, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children. GNH USA supplies Ome Bei Sodbrennen Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ome Bei Sodbrennen Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Erosive gastritis: aids mucosal healing and symptom control. - Helicobacter pylori eradication regimens (as adjunct): enhances effectiveness of antibiotic therapy.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild, transient headache reported in many patients. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Osteoporosis‑related fractures: increased risk of hip, wrist or spine fractures with long‑term use. - Acute interstitial nephritis: sudden kidney inflammation. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Vitamin B12 deficiency: reduced absorption with prolonged therapy. - Liver enzyme elevation: abnormal hepatic function tests.

Before starting Omeprazole, consider the following safety measures.

- Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Evaluate for H. pylori infection: may require combination therapy. - Monitor long‑term use: assess bone health and magnesium levels. - Pregnancy and lactation: use only if clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Omeprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, loss of antiviral efficacy. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, require more frequent monitoring. - Digoxin: increased serum levels, watch for toxicity signs. - Phenytoin: reduced serum concentration, may need dose adjustment.